International Stem Cell Corporation (ISCO)

Market Cap	1.13M +46.1%
Revenue (ttm)	9.39M +10.1%
Net Income	-59.00K
EPS	-0.01
Shares Out	8.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300
Average Volume	6,664
Open	0.1400
Previous Close	0.1400
Day's Range	0.1400 - 0.1400
52-Week Range	0.0885 - 0.2726
Beta	0.21
RSI	47.99
Earnings Date	Mar 27, 2026

About International Stem Cell

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson’s disease, as well as for treating stroke, traumatic brain injury, and Alzheimer’s disease. The company offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, Pr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 32
• Stock Exchange: OTCMKTS
• Ticker Symbol: ISCO

Financial Performance

In 2024, International Stem Cell's revenue was $9.09 million, an increase of 16.64% compared to the previous year's $7.79 million. Losses were -$209,000, 59.5% more than in 2023.